US stocks make unusual movements | Launch of next generation cancer immunotherapy platform HCW Biologics (HCWB.US) soars nearly 70%

According to the Securities Times APP, on Monday, HCW Biologics (HCWB.US) surged nearly 70% to $5.81. On the news front, the company reported that its scientists have developed a second-generation immune therapy drug based on the anti-PD-1 monoclonal antibody, targeting solid tumors, especially pancreatic cancer and ovarian cancer, using its novel proprietary TRBC product discovery and development platform technology.